Scientists at Louisiana State University have discovered that bryostatin-1, a potent PKC modulator at nanomolar concentrations, activates protein kinase C-delta (PKC-delta) causing a near complete blockade of leukocyte
As demonstrated in the Athena trial, Multaq is the only anti-arrhythmic drug to have shown in a clinical study a significant reduction in morbidity and mortality in patients
This new solution is based on Sorin’s implanted cardiac rhythm management (CRM) devices’ ability to send data to a non-invasive monitoring system located at the patient’s home and
Under this agreement, Merck Serono, which is the division for prescription pharmaceuticals of the German pharmaceutical and chemical group Merck KGaA, has granted exclusive worldwide rights to Provenance
Mr Surgenor is currently the president, CEO and director of Cyberkinetics Neurotechnology Systems. Prior to becoming president and CEO of Cyberkinetics Neurotechnology Systems, Mr Surgenor was executive vice
The trial, which was a double-blind, placebo-controlled study, was performed at the Rabin Medical Center, Campus Beilinson in Israel. A total of 21 patients were randomized 2:1 to
Proposals will be jointly developed by EMD Serono and Fast Forward. Merck KGaA, the parent corporation of EMD Serono, will provide up to $19 million in funding. The
Under the terms of the acquisition, MD International’s (MDI’s) 154 employees, its legal entities in Mexico, Brazil and Colombia, as well as sales personnel located in Argentina, Chile,
The proposed merger would involve, among other things, a reverse stock split of shares in Nanobac Pharmaceuticals. When the merger is consummated, the Nanobac Pharmaceuticals name will be
BD Medical – Ophthalmic Systems, a unit of BD, has an exclusive worldwide license from HyperBranch to market OcuSeal for use in ophthalmology. It will immediately begin to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.